• Vemurafenib regimen extends PFS in BRAF V600E-mutant metastatic colorectal cancer

    6 days ago - By Healio

    The addition of vemurafenib to irinotecan and cetuximab improved PFS and response rates among patients with BRAF V600E-mutant metastatic colorectal cancer, according to study results published in Journal of Clinical Oncology.
    “This research was prompted by an appreciation that BRAF inhibition alone was not active in due to an adaptive feedback through the EGFR pathway,” Scott Kopetz, MD, PhD, FACP, professor of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, told Healio. “While the EGFR pathway is not a
    Read more ...